Drug Profile
Research programme: long-acting VEGF antagonists - Bolder BioTechnology
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bolder BioTechnology
- Class
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 10 Nov 2006 Preclinical trials in Cancer in USA (unspecified route)